Lindahl has advised BioArctic AB on its listing on Nasdaq Stockholm. Trading in BioArctics B shares begins today, October 12, 2017.
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of diseases that affect the central nervous system, such as Alzheimer's disease and Parkinson's disease. BioArctic develops innovative treatments based on antibodies (immunotherapy) for neurodegenerative diseases and a potential treatment for complete spinal cord injuries.
In connection with the listing, BioArctic has made an offer to institutional investors in Sweden and abroad, as well as to the public in Sweden. Following the completion of the offer, the total market value of the shares in BioArctic amounts to approximately SEK 2.1 billion. Several major investors entered as BioArctic shareholders, including HMB Healthcare Investments, Handelsbanken Fonder, Second and Third AP Funds, as well as John Wattin / Inbox Capital.
Lindahl's team for BioArctic has worked under the leadership of Mikael Smedeby (responsible partner), Gunnar Mattsson and Erika Svensson, and the team consisted of Emelie Carmhagen Wernoff, Chia Mohtadi, Jonathan Seeskari, Hugo Norlén, Sebastian Fahlgren, Olov Kling, Therese Norenäs, Isabella Rosman, Carolin Martinez, Kerstin Hermelin and Maria Arnoldsson.